Novartis donation: Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services

Princeton – Novartis announced today that Sandoz, its generics and biosimilars division, has started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the US Department of Health and Human Services (HHS) for immediate use in controlled clinical studies. The study will evaluate the medicine’s effectiveness in people who have tested positive for COVID-19. The shipment is part of the previously announced global Novartis donation of 130 million tablets in total to be distributed across a variety of clinical trials and stakeholders internationally.

 

…

/by

Novartis donation: Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services

Princeton – Novartis announced today that Sandoz, its generics and biosimilars division, has started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the US Department of Health and Human Services (HHS) for immediate use in controlled clinical studies. The study will evaluate the medicine’s effectiveness in people who have tested positive for COVID-19. The shipment is part of the previously announced global Novartis donation of 130 million tablets in total to be distributed across a variety of clinical trials and stakeholders internationally.

 

…

/by

Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment

  • Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months1
     
  • Prespecified exploratory analysis based on safety reporting from the three trials, showed fewer major adverse cardiovascular events (MACE) with inclisiran compared to placebo1
     
  • The data are consistent with LDL-C lowering as a strong surrogate for improved patient cardiovascular outcomes2 and …
/by

Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum

  • EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is based on Phase III PREVENT data1
     
  • If approved, Cosentyx would become the first fully-human IL-17A inhibitor indicated for patients in Europe with nr-axSpA
     
  • There are approximately 1.7 million patients with nr-axSpA in the top five EU countries and US, which forms part of the axial spondyloarthritis (axSpA) disease spectrum2
     
  • Cosentyx is …
/by

AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)

  • Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, has been recommended for European Commission (EC) conditional approval for patients with spinal muscular atrophy (SMA) and a clinical diagnosis of Type 1 or SMA patients with up to three copies of the SMN2 gene
     
  • Zolgensma has demonstrated significant and clinically meaningful therapeutic benefit in presymptomatic and symptomatic SMA, including prolonged event-free survival and achievement of motor milestones unseen in natural history of the disease and to date …
/by

Novartis announces further steps to protect and support its associates during the COVID-19 Pandemic

As the coronavirus (COVID-19) situation continues to evolve, our primary concern at Novartis remains the health and safety of our associates and patients globally. With that in mind, this week Novartis announced a range of additional measures to protect and support our associates around the world.

Announced this week, Novartis has extended its guidance for all Novartis associates within Europe, US and Canada to work from home until May 1, 2020, with the exception of those working in laboratories, manufacturing sites and in the field. We continue to assess the situation and adapt …

/by

Visualizing molecular glues

Every cell in the human body is packed with proteins. These large molecules float around, bump into one another and make the stuff of life happen. They turn fuel into energy. They dispose of trash. They read genetic codes and coax cells to divide.

In some cells, naturally occurring “molecular glues” float among these proteins. Like crafty matchmakers, these small molecules stick proteins together. By doing so, they may change a cell’s destiny.

Drug hunters at the Novartis Institutes for BioMedical Research (NIBR) think these tiny matchmakers also have the potential to change …

/by

Caring for someone with heart failure

Available 24 hours a day or living 24 hours away – the carer of someone with heart failure comes in all guises. But where they are all the same is in the important role they play in helping someone with heart failure live with their condition.

Heart failure is complex. It is debilitating and potentially life-threatening. It causes the heart muscle to become stiff or weak, meaning it’s unable to pump enough blood to meet the demands of the body.1 This leaves heart failure patients exhausted and short of breath, severely limiting the activities they are able to do.1 …

/by

Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic alongside Bill & Melinda Gates Foundation

  • Collaboration to address product development and scale up challenges posed by current pandemic 

Basel, March 26, 2020 — Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify effective and scalable solutions to the pandemic that is affecting billions worldwide. Effects on health systems, …

/by

Sandoz announces new country head for Japan

  • Shingo Iwamoto appointed country head for Sandoz in Japan
  • Shingo Iwamoto will also oversee Japanese business of Aspen Global Incorporated (AGI), successfully acquired by Sandoz on February 1 this year
  • Japan, world’s third largest generics and off-patent market, is central to Sandoz global strategy

Tokyo, March 25, 2020 – Sandoz announced today that Shingo Iwamoto, currently President and representative director of Aspen Japan, has been appointed Country Head for Sandoz in Japan with effect from April 1, 2020. He will …

/by